Document is current
Any future updates will be listed below
-
Authors
Xu, Tongpeng
Bai, Jianan
Zhao, Kun
Chen, Xiaofeng
Wang, Shuhui
Zhu, Shusheng
Sun, Chongqi
Zhao, Chenhui
Wang, Ting
Zhu, Ling
Hu, Meizhen
Pang, Fei
Zhang, Junling
Wang, Wei
Shu, Yongqian
Li, Fang
Zhou, Yue
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05469061 at ClinicalTrials.govDocuments that mention this clinical trial
Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study
https://doi.org/10.1245/s10434-024-16033-x
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82172889, 82372593)
Natural Science Foundation of Jiangsu Province (BK20211381)
- License Information
-
More Information
Article History
Received: 17 June 2024
Accepted: 30 July 2024
First Online: 23 August 2024
Disclosure
: Shuhui Wang is an employee of Beigene Co. Ltd, China, Meizhen Hu and Fei Pang are employees of OrigiMed, Shanghai, China, and Junling Zhang is an employee of 3D Medicines Inc. China. The remaining authors declare no competing interests.
: The study was approved by the Ethics Committee of Jiangsu Provincial Hospital (2021-SR-372). All patients provided voluntary written informed consent before the study.
